Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for combination trial

In December, Gilead closed out a year-long spending spree on cancer drugs by closing a deal much closer to their roots: a $1.7 billion deal for a German biotech focused on hepatitis delta virus. It was a bet on a drug they’d watched for years and a signal, Gilead virology…

Click to view original post